Risk of neurologic or immune-mediated adverse events after COVID-19 diagnosis in the United States. Fisher SS, Lindaas A, Muthuri SG, Lloyd PC, et al. PLoS One 2025;20:e0333704.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Fisher SS, Lindaas A, Muthuri SG, Lloyd PC, et al. Risk of neurologic or immune-mediated adverse events after COVID-19 diagnosis in the United States. PLoS One 2025;20:e0333704.
PMID: 41284649